Upstream Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-79.18	-62.81	-20.54	-23.87
Depreciation & Amortization	0.12	0.09	0.06	0.01
Loss (Gain) From Sale of Investments	-2.77	-1.66	-1.26	-
Stock-Based Compensation	8	6	3.43	1.28
Other Operating Activities	0.3	-2.68	-15.31	0.15
Change in Accounts Receivable	0.17	-0.52	0.31	-0.41
Change in Accounts Payable	3.34	2.02	1.28	0.46
Change in Other Net Operating Assets	-12.75	0.37	-5.9	3.36
Operating Cash Flow	-82.78	-59.17	-37.93	-19.02
Capital Expenditures	-0.51	-0.51	-0.14	-0.08
Investment in Securities	-286.21	-58.97	-82.7	-
Investing Cash Flow	-286.72	-59.49	-82.84	-0.08
Issuance of Common Stock	263.5	272.88	0.12	-
Other Financing Activities	-4.01	-3.97	-	-0.04
Financing Cash Flow	409.49	418.91	129.55	9.96
Net Cash Flow	40	300.25	8.78	-9.14
Free Cash Flow	-83.29	-59.68	-38.07	-19.1
Free Cash Flow Margin	-3627.44%	-2518.27%	-1599.58%	-1576.15%
Free Cash Flow Per Share	-3.16	-4.36	-12.89	-6.82
Levered Free Cash Flow	-	-40.98	-25.96	-
Unlevered Free Cash Flow	-	-40.98	-25.96	-
Change in Net Working Capital	-	-2.04	4.23	-

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q